BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32106507)

  • 1. Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety.
    Shoda T; Ohoka N; Tsuji G; Fujisato T; Inoue H; Demizu Y; Naito M; Kurihara M
    Pharmaceuticals (Basel); 2020 Feb; 13(3):. PubMed ID: 32106507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.
    Ohoka N; Tsuji G; Shoda T; Fujisato T; Kurihara M; Demizu Y; Naito M
    ACS Chem Biol; 2019 Dec; 14(12):2822-2832. PubMed ID: 31580635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted protein degradation and drug discovery.
    Naito M
    J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs.
    Naito M; Ohoka N; Shibata N; Tsukumo Y
    Front Chem; 2019; 7():849. PubMed ID: 31921772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.
    Ishikawa M; Tomoshige S; Demizu Y; Naito M
    Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32326273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
    Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNIPERs-Hijacking IAP activity to induce protein degradation.
    Naito M; Ohoka N; Shibata N
    Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
    Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
    Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
    Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
    Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands.
    Naganuma M; Ohoka N; Tsuji G; Tsujimura H; Matsuno K; Inoue T; Naito M; Demizu Y
    ACS Med Chem Lett; 2022 Jan; 13(1):134-139. PubMed ID: 35059133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
    Ma Z; Ji Y; Yu Y; Liang D
    Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention.
    Puppala D; Lee H; Kim KB; Swanson HI
    Mol Pharmacol; 2008 Apr; 73(4):1064-71. PubMed ID: 18178667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent Ligands for Protein Degradation in Drug Discovery.
    Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
    Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
    Ohoka N; Shibata N; Hattori T; Naito M
    Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
    Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
    Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of DNA Aptamer-Based PROTACs That Degrade the Estrogen Receptor.
    Tsujimura H; Naganuma M; Ohoka N; Inoue T; Naito M; Tsuji G; Demizu Y
    ACS Med Chem Lett; 2023 Jun; 14(6):827-832. PubMed ID: 37312841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.